Synthesis of novel WAY 100635 derivatives containing a norbornene group and radiofluorination of [18F]AH1.MZ as a serotonin 5-HT1A receptor antagonist for molecular imaging

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 52, Issue 6, 2009, Pages 201-207

  Herth, Matthias M ^a   Kramer, Vasko ^a   Rösch, Frank ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

5 HT1A antagonist; PET; Radiofluorination; WAY 100635; 18F AH1.MZ

Indexed keywords

CHELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

5-HT1A ANTAGONIST; ARYLPIPERAZINES; IN-VIVO; MZ; NORBORNENES; PSYCHIATRIC DISORDERS; RADIOFLUORINATION; RECEPTOR ANTAGONISTS; WAY 100635; [18F]AH1.;

MOLECULAR IMAGING;

FLUORINE 18; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORBORNENE DERIVATIVE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR;

ARTICLE; DRUG SYNTHESIS; FLUORINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RECEPTOR AFFINITY;

EID: 66949141578     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.1589     Document Type: Article

References (17)

1. H. G. Baumgarten, M. Gother, Handbook of Experimental Pharmaceuticals, Vol.129, Springer, Berlin, 1997.
2. G. R. Martin, R. M. Eglen, D. Hoyer, M. W. Hamblin, F. Yocca, N. Y. Ann, Acad. Sci. 1998, 861, 31-37.
3. N. M. Barnes, T. Sharp, Neuropharmacology 1999, 38, 1083-1152.
4. D. Hoyer, J. P. Hannon, G. R. Martin, Pharmacol. Biochem. Behav. 2002, 71, 533-554.
5. S. Hillver, L. Bjork, Y. Li, B. Svensson, S. Ross, N. Andèn, U. J. Hacksell, Med. Chem. 1990, 33, 1541-1544.
6. J. P. Gardner, C. A. Fornal, B. L. Jacobs, Neuropsychopharmacology 1997, 17, 72-81.
7. R. A. Glennon, Neurosci. Biobehav. Rev. 1990, 14, 35-47.
8. W. Kostowski, A. Plaznik, T. Archer, New Trends Exp. Clin. Psychiatry 1989, 5, 91-116.
9. E. Seifritz, M. S. Stahl, J. C. Gillin, Brain Res. 1997, 759, 84-91.
10. P. R. Saxena, Pharmacol. Ther. 1995, 66, 339-368.
11. World Health Organization, WHO Fact Sheet Number 265, The World Health Organization, Geneva, Switzerland, 2001.
12. M. J. Fava, Clin. Psychiatry 2003, 64, 30-34.
13. C. A. Mathis, N. R. Simpson, K. Mahmood, P. E. Kinahan, M. A. Mintun, Life Sci. 1994, 55, 403-407.
14. A. Plenevaux, D. Weissmann, J. Aerts, C. Lemaire, C. Brihaye, C. Degueldre, D. Le Bars, D. Comar, J. F. Pujol, A. Luxen, J. Neurochem. 2000, 75, 803-811.
15. F. Fiorino, E. Perissutti, B. Severino, V. Santagada, D. Cirillo, S. Terracciano, P. Massarelli, G. Bruni, E. Collavoli, C. Renner, G. Caliendo, J. Med. Chem. 2005, 48, 5495-5503.
16. M. M. Herth, F. Debus, M. Piel, M. Palner, G. M. Knudsen, H. Lüddens, F. Rösch, Bioorg. Med. Chem. Lett. 2008, 18, 1515-1519.
17. A. Bauman, M. Piel, R. Schirrmacher F. Rösch, Tetrahedron Lett. 2003, 44, 9165-9167.